GlassScriptPhysician profile
David H Freeman
NPI 1205894417
$2,821.14
in general payments reported to CMS, 2019-2025
14 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $145 · 2024: $715 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,499 · Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,499.22 |
| Food and Beverage | $1,321.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,499.22 | 2025 | |
| Viiv Healthcare Company | $305.55 | 2024 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $282.29 | 2024-2025 | |
| Gilead Sciences, INC. | $181.57 | 2025 | Yeztugo |
| Glaxosmithkline, LLC. | $128.66 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Novo Nordisk INC | $101.19 | 2024-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $90.16 | 2024-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $51.86 | 2024-2025 | Heplisav-B |
| Pfizer INC. | $42.96 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $38.73 | 2024 | Vaxneuvance, Vaxelis, Gardasil |
| Regeneron Healthcare Solutions, INC. | $37.07 | 2025 | Dupixent |
| Phadia US INC. | $25.37 | 2024 | Immunocap |
| Dexcom, INC. | $21.38 | 2023 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $15.13 | 2025 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.